Breakthrough Prostate Cancer Immunotherapy VIR-5500 Delivers Stunning Early Trial Results

Early-stage phase 1 trials of VIR-5500, a PSMA-targeting T-cell engager developed by Vir Biotechnology, have produced remarkable results in 58 men with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). Presented at the ASCO Genitourinary Cancers Symposium, the data revealed that at the highest doses, 82% of 17 patients experienced at least a 50% drop in prostate-specific antigen (PSA) levels, 53% saw a 90% reduction, and some achieved near-complete declines. Nearly half of participants had measurable tumor shrinkage, including complete resolution of liver metastases in specific cases, with 88% reporting only mild side effects.

The drug's innovative 'cloaking' mechanism, using PRO-XTEN dual-masking technology, keeps it inactive until it reaches prostate cancer cells expressing PSMA, minimizing toxicity and allowing longer circulation in the bloodstream for fewer doses. This addresses key limitations of prior immunotherapies, which often failed to shrink prostate tumors and caused severe immune-related reactions. No dose-limiting toxicities were observed, even without prophylactic treatments, marking a significant safety advance in T-cell engagers.

These findings matter profoundly for mCRPC patients who have exhausted standard therapies like taxanes, offering hope for durable responses and improved quality of life, as seen in cases of pain reduction and remission. Led by researchers at The Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust, the results validate the approach and have drawn praise from experts like Professor Johann de Bono, who called them 'profound' for advanced disease.

Vir Biotechnology plans to advance VIR-5500 into larger phase 2 and 3 trials to assess long-term outcomes and potential cures. A recent global collaboration with Astellas further bolsters development, positioning this as a potential best-in-class therapy in prostate cancer treatment.